Ascentage Pharma Group International announced on July 19, 2026, the submission of an automatic shelf registration statement on Form F-3 with the SEC to establish an at-the-market (ATM) offering program. The program allows the company to sell American depositary shares (ADSs) for an aggregate offering price of up to $200 million through sales agents Citigroup, Deutsche Bank, and BTIG. Proceeds are intended for the commercialization of Olverembatinib and Lisaftoclax, clinical trials, and general corporate purposes. The company operates in the biotechnology industry and develops drug candidates for oncology and other diseases.

Ascentage Pharma Group International issued an announcement on July 13, 2026, regarding further grants of awards under its 2021 Restricted Share Unit (RSU) Scheme, 2022 RSU Scheme, and the Post IPO Share Option Scheme. The company is a biopharmaceutical firm focused on developing innovative medicines.

On June 29, 2026, Ascentage Pharma Group International announced the further grant of awards under its 2021 and 2022 Restricted Share Unit (RSU) schemes, as well as the further grant of options under its Post IPO Share Option Scheme. The company operates in the biotechnology industry and develops innovative small molecule drugs for oncology and hematology.

On June 14 and 15, 2026, Ascentage Pharma released multiple clinical updates presented at the EHA 2026 Congress. The company operates in the biotechnology industry and develops innovative medicines for oncology and autoimmune diseases.

On June 11, 2026, Ascentage Pharma Group International announced that the trustee for the company's 2022 Restricted Share Unit (RSU) Scheme has purchased shares. The company operates in the biotechnology industry and develops innovative small-molecule targeted therapies for cancer and autoimmune diseases.